Research Article

Updated Meta-Analysis Assessing Effects of Baduanjin on Cardiopulmonary Functions of Patients with Coronary Heart Disease

Dongsheng Wang and Jun Xu

1. Introduction

Coronary heart disease (CHD), also known as coronary artery disease, is the most common cause of death worldwide, affecting more than 11 million people in China, and the number of patients is increasing by 20% every year [1]. CHD is a risk factor for acute myocardial infarction, unstable angina, cardiac arrest, and heart failure [2]. Cardiac rehabilitation (CR) is complex and multifaceted support for patients with CHD to improve their health and prognosis status [3]. Of which, exercise training is one of the core modes of CR and has been proven to effectively enhance the patient’s endurance and prolong their physical activity time [4]. Its potential benefits also include improved endothelial function, myocardial blood flow reserve, and psychological stress in patients with CHD [5]. A meta-analysis of 14,486 patients with CHD found that exercise-based CR can reduce cardiovascular mortality and the risk of hospitalization [6]. Bai and Wang concluded that lighter activity intensity was independently correlated with health indicators of cardiovascular metabolism and had the strongest correlation with triglycerides and lipid accumulation products [7]. However, the training intensity that CHD patients receiving exercise-based CR therapy can tolerate is an important concern, and an appropriate stimulus is needed to trigger positive physiological application in order to improve peak VO2 as
Evidence-Based Complementary and Alternative Medicine

much as possible [8]. Therefore, optimizing exercise prescription is significant for the recovery of cardiopulmonary function in patients with CHD.

Baduanjin, a traditional Chinese qigong, has a history of more than 1,000 years as a form of exercise. It is characterized by symmetrical body postures and movements and allows the interaction between thought and breath to coexist in a harmonious manner [9]. Baduanjin is a set of independent and complete fitness systems, and its eight decomposing movements have their own effects on specific parts of the body and, therefore, play an integrated adjustment [10]. According to the gold standard of exercise intensity VO2, Baduanjin is a kind of moderate-intensity aerobic exercise and also a safe and effective family CR exercise mode, with an average energy consumption of $23.3 \pm 4.4$ kcal [11]. The physical health benefits of Baduanjin include treating hyperlipidemia, ischemic stroke, sleep disorders, and knee osteoarthritis, as well as improving mental health, quality of life, balance, and flexibility of patients [10, 12]. In addition, studies also highlighted the physiological benefits of Baduanjin practice, including improvements in cardiopulmonary functions [13]. There have been related randomized controlled studies (RCTs) to explore the effect of Baduanjin on cardiopulmonary function recovery in patients with CHD, but the sample size of a single study is relatively small (ranging from 40 to 120), and the selection of evaluation indicators is inconsistent [14–16]. Meanwhile, it is still controversial whether CHD patients with percutaneous coronary intervention (PCI) had a significant difference in left ventricular ejection fraction (LVEF) with and without Baduanjin [15, 16]. Therefore, it is necessary to further expand the sample size by gathering samples of eligible RCTs as many as possible, to discuss the effect of Baduanjin on cardiopulmonary function recovery in patients with CHD.

This study summarized several RCT reports and conducted a more comprehensive and objective evaluation of the difference between Baduanjin on cardiopulmonary function indicators through this meta-analysis, so as to explore the impact of Baduanjin on cardiopulmonary function recovery for patients with CHD. Additionally, we also assessed the extrapolation of the results so as to promote the benefits of this sport globally. This study also provides evidence for patients with CHD to choose a superior pattern of rehabilitation nursing.

2. Methods

All procedures were performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [17].

2.1. Retrieval Strategies. Both English and Chinese databases, including PubMed, Embase, the Cochrane library, Wanfang data, China National Knowledge Infrastructure, China Science and technology journal database, and China Biology Medicine disc were used in this study for bibliographic retrieval. The search keywords included Baduanjin AND (“coronary heart disease” OR “ischemic heart disease” OR “Ischemic cardiomyopathy” OR “myocardial infarction” OR “acute coronary syndrome” OR stenocardia OR “coronary artery disease”). The retrieval procedures and results of the English databases are shown in Tables S1–S3. Search deadline is August 9, 2022, with no language restrictions. Furthermore, the paper literature and the references included in relevant reviews were manually searched in this study.

2.2. Literature Screening. Inclusion criteria: (1) the subjects were patients with CHD; (2) the studies discussed the difference of intervention effect on cardiopulmonary function in CHD patients of Baduanjin vs. control (maintain original habit of exercise), or between Baduanjin + exercise rehabilitation (ER, including aerobic training, aerobic walking training, low intensity aerobic combined resistance exercise, et al.) vs. ER; (3) randomized controlled trials; and (4) the studies reported one or more of the following outcomes: N-terminal pro-B-type natriuretic peptide (NT-proBNP), LVEF, 6 min walk test (6MWT), peak VO2, anaerobic threshold (AT) VO2, maximal voluntary ventilation (MVV), AT ventilation volume (VE, AT), O2 pulse, metabolite equivalents (METs), and AT METs.

Exclusion criteria: (1) reviews, conference abstracts, and comments; (2) the postintervention measurement results (mean ± standard deviation) were not reported or could not be obtained according to literature information; and (3) for repeated publications or multiple articles with the same data, only the one with the most complete research information was included and the rest were excluded.

2.3. Data Extraction and Quality Assessment. Two researchers independently conducted literature screening and data extraction according to the above screening criteria. Information to be extracted includes: the first author, publication year, country, demographic characteristics of study subjects (age, gender, sample size, disease course, and CHD types), intervention plan, follow-up period, and study outcomes. The Cochrane Collaboration’s tool for assessing risk was utilized to evaluate the methodological quality of the included studies [18]. In the case of disagreement in the process of literature data extraction and quality evaluation, a consensus was reached after a group discussion with the third author.

2.4. Statistical Analysis. Weighted mean difference (WMD) and 95% confidence interval (95%CI) were used as the effect size indicators of continuous variables (including NT-proBNP, LVEF, 6MWT, and other cardiopulmonary function indicators) to evaluate whether the intervention effect of Baduanjin on the cardiopulmonary function of CHD patients was statistically significant. The heterogeneity test was then generated using Cochran’s Q test and $I^2$ test [19]. The meta-analysis was performed using a random effect model when a significant heterogeneity exists at $P < 0.05$ and/or $I^2 > 50$. If heterogeneity was not significant ($P ≥ 0.05$ and
I^2 \leq 0.5), the fixed effect model was used for meta-analysis [20]. The effects of follow-up time, intervention plan, and disease course on heterogeneity and combined outcomes were then assessed by subgroup analysis. Finally, the funnel plot and Egger test were used to evaluate whether there was significant publication bias among included studies [21]. Statistical analysis was generated using RevMan 5.3 and Stata12.0.

3. Results

3.1. Literature Retrieval. The literature search process and results are described in Figure 1. Using the public databases, a total of 457 pieces of literature were searched, of which 193 duplicate articles were eliminated, and 173 studies did not meet inclusion criteria after browsing titles and abstracts. Then, eight of the remaining 20 papers were eliminated after the full text reading. Among them, four studies did not report study outcomes; three studies were not RCTs; and one was a review. Finally, a total of 12 pieces of literature [14–16, 22–30] were included in this meta-analysis.

3.2. Study Characteristics and Quality Assessment. As shown in Table 1, the 12 included studies were all carried out in China and published between 2016 and 2021 with a sample size of 40–120. By gathering these studies, a total of 468 cases and 460 controls were included in this meta-analysis. Among them, there were 588 male patients and 340 female patients in all enrolled studies. In terms of gender, there were 588 male patients and 340 female patients in all included studies. In terms of CHD types, the research objects of five literature [15, 16, 23–25] were CHD with PCI; two [14, 29] were CHD with chronic heart failure (CHF); one [27] was stable CHD with PCI or coronary artery bypass grafting (CABG), one [30] was CHD with percutaneous transluminal coronary angioplasty (PTCA); and the remaining three studies [22, 26, 28] did not report the specific CHD types. In addition to routine nursing (including diet guidance, pharmacological nursing, and mental nursing), three studies [14, 24, 28] reported the effects of Baduanjin on cardiopulmonary function in CHD patients of Baduanjin + ER vs. ER (AWT [14], AT [28], and low-intensity aerobic combined resistance exercise [24]), while the rest of the studies explored the differences between patients with and without (maintain the original habit of exercise) Baduanjin. The follow-up time of RCTs was 0.5 to 6 months. The detailed information on age, disease course, exercise rehabilitation program and the New York Heart Association (NYHA) classification are shown in Table 1.

The methodological quality evaluation results of the included literature are shown in Figure S1. Except for the study of Chen et al., other studies have relatively high degrees of bias. As the included studies did not clearly describe whether allocation concealment and outcome measurement blindness were implemented and did not measure the blinding of participants and personnel, the bias therefore mainly focused on selection bias, performance bias, and detection bias. Overall, the methodological quality of the included studies was low.

3.3. Meta-Analysis on Effects of Baduanjin on Outcome Indicators for Patients with CHD. The differences in 6MWT, LVEF, and NT-proBNP were then compared between CHD patients with and without Baduanjin. Four studies [14, 23, 25, 29] reported the difference in 6MWT, and \( I^2 = 96\% \) and \( P < 0.00001 \) indicated a significant heterogeneity among these studies. Therefore, the random effect model was conducted and the combined results suggested WMD (95% CI) = 40.14 (8.45, 71.83) meters and \( P = 0.01 \) (Figure 2(a)). Eight studies [14–16, 23, 26, 28–30] reported the differences in LVEF, but the significant heterogeneity existed (\( I^2 = 60\% \), \( P = 0.01 \)), and the random effect model suggested the combined results of WMD (95%CI) = 3.90 (2.40, 5.40)% and \( P < 0.00001 \) (Figure 2(b)). Four studies [14, 15, 29, 30] reported the differences in NT-proBNP, and there was no significant heterogeneity among these studies (\( I^2 = 0\% \), \( P = 1.00 \)), followed by the combined results of WMD (95%CI) = −52.73 (−84.55, −20.91) pg/mL and \( P = 0.001 \) using the fixed effect model (Figure 2(c)). These results indicate that Baduanjin may affect the levels of 6MWT, LVEF, and NT-proBNP in patients with CHD, despite some heterogeneities.

Then two studies [24, 27] were included to compare the difference in VO_{2peak} while peak VO_{2peak} and AT VO_{2peak} showed no significant heterogeneity (\( I^2 < 50\% \), \( P > 0.05 \)) with the combined estimate of WMD (95%CI) = 0.91 (0.52, 1.29) ml/kg/min and WMD (95%CI) = 1.31(0.98, 1.64) ml/kg/min, respectively, and \( P < 0.00001 \) (Figure 3(a)). By comparing the difference in MVV (Figure 3(b)), the combined results of four studies [22, 24, 26, 27] were WMD (95%CI) = 9.46 (3.88, 15.04) L/min, \( P = 0.0009 \) with a significant heterogeneity (\( I^2 = 82\% \), \( P = 0.0007 \)). Figure 3(b) also shows the differences in VE, AT based on two studies [22, 27] and the combined estimate were WMD (95%CI) = 4.28 (2.49, 6.04) L/min, \( P < 0.00001 \) with a nonsignificant heterogeneity (\( I^2 = 0\% \), \( P = 0.78 \)). To summarize the differences in O_2 pulse, \( P < 0.00001 \) and the combined results were WMD (95%CI) = 1.36 (0.96, 1.77) ml/time, \( P < 0.00001 \), and WMD (95%CI) = 0.80 (0.54, 1.05), \( P < 0.00001 \) for O_2 pulse and METs, respectively. The differences in these indicators between CHD with and without Baduanjin indicated that Baduanjin can effectively improve the recovery of cardiopulmonary function in CHD patients.

3.4. Subgroup Analysis. Because of the limited literature on most outcome indicators, the subgroup analysis was only generated on LVEF in this meta-analysis. As shown in Table 2 and Figure S2, it was found that follow-up time, rehabilitation scheme, and new-onset status are not the sources of the significant heterogeneity. Furthermore, in the subgroups of follow-up time <1 month and new-onset, the estimates were not significant (\( P = 0.71 \)), but the results in
other subgroups were statistically significant ($P < 0.05$), consistent with the original combined results.

3.5. **Publication Bias Test.** Publication bias was analyzed on LVEF, the most studied outcome index, using the funnel plot and Egger test. The results show the symmetric scatter distribution in the funnel plot with a $P = 0.983 > 0.05$ of the Egger test (Figure 4). Qualitative and quantitative tests indicated that there was no significant publication bias on LVEF among the included studies.

### 4. Discussion

With the improvement of living standards, CHD has increasingly become an important threat to humans all over the world, and exercise-based CR has become an effective postoperative treatment for patients with CHD. It has been proven that regular physical activity can improve athletic ability as well as increase peak oxygen consumption (+15%) and peak anaerobic threshold (+11%) [31–33]. In addition, peak VO2 was associated with lower mortality in patients with coronary artery disease, and the survival rate of CHD patients can increase by nearly 15% with each increase of 1 mL/kg/min of exercise capacity [34, 35]. As a highly adaptable form of exercise, Baduanjin can be carried out anywhere and at any time, without special equipment or a large time investment. Therefore, it is beneficial to incorporate Baduanjin into a comprehensive CR program, but its effect on postoperative cardiac recovery in patients with CHD is worth discussing.

Through this meta-analysis, we found significant differences in the levels of peak VO2, LVEF, 6MWD, and other rehabilitation indicators between CHD patients who received and did not receive Baduanjin training, suggesting that Baduanjin can effectively promote the recovery of cardiopulmonary function in CHD patients. Wang et al. supported our conclusion and suggested that Baduanjin exercise can improve LVEF, cardiac output, and stroke output, and reduce resting myocardial oxygen consumption in elderly patients [36]. We also performed a subgroup analysis of LVEF, and the results were consistent with the combined estimate. However, in terms of the 6MWD indicator, the current research conclusions are still controversial. Zhang and Chang suggested no statistically significant difference in the level of 6MWD between exercise and nonexercise CHD patients with PCI ($P = 0.71$), and it is therefore uncertain whether exercise can improve cardiac function or reduce the incidence of adverse cardiovascular events in patients with CHD after PCI [37]. In addition, the cardiopulmonary exercise test is a practical tool to evaluate the exercise capacity of cardiac failure patients, in which peak VO2, VO2, VAT, and VE/VCO2 are important indicators [38]. Yu et al. enrolled 120 patients with ischemic heart failure in CR training and found that patients who received an additional 45 minutes of Baduanjin training showed significant improvement in exercise ability indexes.

**Figure 1:** The literature search procedures and results of this meta-analysis.

---

| Records identified through database searching (n = 457) |
| --- |
| PubMed (n=10), Emebase (n=10), the Cochrane Library (n=12), CNKI (n=110), CQVIP (n=75), Wanfang (n=145), CBM (n=95) |
| Records after duplicates removed (n = 193) |
| Records screened title/abstract (n = 193) |
| Records excluded (n = 173) |
| Full-text articles assessed for eligibility (n = 20) |
| Full-text articles excluded with reasons (n = 8) |
| 4 without interested outcomes; 3 not RCT; 1 review. |
| Studies included in quantitative synthesis (meta-analysis) (n = 12) |

---

4. Evidence-Based Complementary and Alternative Medicine
| Study          | Type of patients | Follow-up, months | Rehabilitation exercise program |  n, m/f | Age, years | Course of CHD, years | NYHA |
|---------------|------------------|------------------|-------------------------------|--------|------------|---------------------|------|
| Chen et al.   | CHD with PCI     | 6                | Baduanjin Control             | 43, 29/14 | 60.0 ± 10.9 | New-onset           | 43   |
|               |                  |                  | 30 min/day, 5 days/week       | 39, 30/9 | 61.5 ± 11.5 | New-onset           | 39   |
| Kang et al.   | Stable CHD with CHF | 6                | Baduanjin + AWT AWT           | 38, 21/17 | 68.4 ± 5.0 | 21 I/II/17 III      | 19 II/19 III |
|               |                  |                  | 30 min/day, 5 days/week       | 38, 23/15 | 69.3 ± 5.3 | NR                  |      |
| Liang         | CHD              | 1                | Baduanjin Control             | 40, 22/18 | 56.4 ± 4.5 | 4.5 ± 2.3           | 40   |
|               |                  |                  | 30 min/day, 3-4 days/week     | 40, 23/17 | 56.6 ± 4.3 | 4.3 ± 1.8           | 40   |
| Liao          | CHD with PCI     | 1                | Baduanjin Control             | 20, 12/8  | 54.6 ± 5.5 | 6.1 ± 2.4           | NR   |
|               |                  |                  | 30 min/day, 3 days/week       | 20, 11/9  | 54.8 ± 5.7 | 5.9 ± 2.3           | NR   |
| Ou            | CHD with PCI     | 3                | Baduanjin Control             | 40, 21/19 | 52.2 ± 3.4 | NR                  | NR   |
|               |                  |                  | 30-60 min/time, 2 times/day   | 40, 22/18 | 52.0 ± 3.4 | NR                  | NR   |
| Shi et al.    | CHD with PCI     | 3                | Baduanjin + ER *              | 60, 47/13 | 58.3 ± 5.8 | 5.80 ± 2.61         | 60   |
|               |                  |                  | 15-30 min/day, 2-3 days/week  | 60, 52/8  | 58.9 ± 6.5 | 6.10 ± 2.96         | 60   |
|               |                  |                  | ER as control group           |          |            |                     |      |
|               |                  |                  | 60 min/day, 2-3 days/week     |          |            |                     |      |
| Tang          | CHD with PCI     | 3                | Baduanjin Control             | 46, 37/9  | 60.0 ± 8.7 | NR                  | 46   |
|               |                  |                  | 30 min/day, 5 days/week       | 47, 38/9  | 61.4 ± 9.2 | NR                  | 47   |
| Wang et al.   | CHD              | 3                | Baduanjin Control             | 32, 34/30# | 56.8 ± 12.3 | NR                  | NR   |
|               |                  |                  | 40 min/day, 5 days/week       | 32       | 56.8 ± 12.3 | NR                  | NR   |
| Wang et al.   | Stable CHD with PCI or CABG | 1                | Baduanjin Control             | 29, 21/8  | 64.3 ± 5.6 | 5.49 ± 5.15         | 3 I/II/2 II/III |
|               |                  |                  | 30 min/day, 5-7 days/week     | 29, 16/13 | 64.4 ± 6.6 | 6.15 ± 4.65         | 5 I/II/III |
| Xin           | CHD              | 3                | Baduanjin + AT AT             | 44, 17/27 | 58.3 ± 7.1 | 4.37 ± 0.88         | 44   |
|               |                  |                  | 30 min/day, 3 days/week       | 44, 16/28 | 57.2 ± 7.2 | 4.32 ± 0.87         | 44   |
| Xiong et al.  | CHD with CHF     | 3                | Baduanjin Control             | 33, 20/13 | 70.3 ± 6.4 | NR                  | 33   |
|               |                  |                  | 30 min/day, 5-7 days/week     | 30, 18/12 | 69.7 ± 7.2 | NR                  | 30   |
| Zhang et al.  | CHD with PTCA    | 0.5              | Baduanjin Control             | 43, 28/15 | 57.4 ± 13.1 | New-onset           | NR   |
|               |                  |                  | 30 min/day, 7 days/week       | 41, 30/11 | 55.0 ± 16.5 | New-onset           | NR   |

AT, aerobic training; AWT, aerobic walking training; CABG, coronary artery bypass grafting; CHD, coronary heart disease; CHF, chronic heart failure; ER, Exercise rehabilitation ( * , means low intensity aerobic combined resistance exercise); F, female; M, male; NR, not reported; NYHA, The New York Heart Association; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty. #, sample size of male/female patients of total participants.
including 6MWT, peak VO\textsubscript{2}, VE/VCO\textsubscript{2}, LVEF, and NT-proBNP [39]. This conclusion demonstrates the benefit of Baduanjin in improving cardiopulmonary function in patients with heart failure, which is considered to be an end-stage state of cardiovascular disease, including CHD [40], thus supporting our findings to a certain degree.

To highlight the advantages of this study, we resolved the dispute over the inconsistent results of the original studies with objective results. In this meta-analysis, the combined results of all outcome indicators supported the benefit of Baduanjin exercise in China, and it is not as popular as Tai Chi. The main reason is that Baduanjin is a traditional health exercise that plans to carry out routine rehabilitation training had a significantly better recovery effect on LVEF than the control group. Furthermore, there was no significant publication bias in this study, and the results were highly reliable. However, there are still some defects in this study. First of all, there was relatively large heterogeneity among the included studies, and differences in follow-up time, CHD type, and rehabilitation plan would affect the results of this meta-analysis. Second, the methodological quality of the included studies was unsatisfactory, and the control of selection bias, implementation bias, and measurement bias was not carried out strictly according to the standard of RCT. Additionally, the sample size and rehabilitation indicators except for LVEF of included studies are limited, which were not suitable for auxiliary analyses such as subgroup analysis and publication bias test. Therefore, the credibility and stability of meta-analysis results need further exploration and verification. Finally, all the included studies were carried out in China. The main reason is that Baduanjin is a traditional health exercise in China, and it is not as popular as Tai Chi. Therefore, there are few available data based on other regions.

### Table 1: Study Subgroup Analysis

| Study or Subgroup | Experimental | Control | Mean Difference | Mean Difference |
|-------------------|--------------|---------|-----------------|-----------------|
|                   | Mean | SD | Total | Mean | SD | Total | (%) | IV, Random, 95% CI | IV, Random, 95% CI |
| Kang, ZL 2021     | 336.36 | 36.8 | 38 | 316.3 | 30.98 | 38 | 25.1 | 20.06 [4.77, 35.35] |
| Ou, JZ 2020       | 505.65 | 32.18 | 40 | 444.5 | 30.09 | 40 | 25.4 | 61.15 [47.35, 74.95] |
| Xiong, XH 2016    | 561.35 | 18.37 | 46 | 533.74 | 11.13 | 47 | 26.4 | 7.61 [1.42, 13.80] |
| Total (95% CI)    | 157   |       |     | 155   |       |     | 100.0 | 40.14 [8.45, 71.83] |

Heterogeneity: Tau\textsuperscript{2} = 978.63; Chi\textsuperscript{2} = 69.48, df = 3 (P < 0.00001); F = 96%

Test for overall effect: Z = 2.48 (P = 0.01)

### Table 2: Study Subgroup Analysis

| Study or Subgroup | Experimental | Control | Mean Difference | Mean Difference |
|-------------------|--------------|---------|-----------------|-----------------|
|                   | Mean | SD | Total | Mean | SD | Total | (%) | IV, Random, 95% CI | IV, Random, 95% CI |
| Chen, MG 2020     | 58.74 | 10.1 | 43 | 57.79 | 9.56 | 39 | 8.1 | 0.95 [−3.31, 5.21] |
| Kang, ZL 2021     | 50.33 | 6.39 | 38 | 46.89 | 5.93 | 38 | 13.1 | 3.44 [0.67, 6.21] |
| Liao, XX 2020     | 64.78 | 9.47 | 20 | 56.31 | 10.54 | 20 | 4.7 | 8.47 [2.26, 14.68] |
| Ou, JZ 2020       | 59    | 4.04 | 40 | 52.38 | 3.68 | 40 | 18.2 | 6.62 [4.93, 8.31] |
| Wang, HQ 2018     | 65.32 | 1.12 | 32 | 62.56 | 3.65 | 32 | 20.1 | 2.76 [1.44, 4.08] |
| Xin, YR 2018      | 63.21 | 7.81 | 44 | 60.23 | 5.34 | 44 | 13.0 | 2.98 [0.18, 5.78] |
| Xiong, XH 2016    | 48.9  | 5.8  | 33 | 44.7  | 4.9  | 30 | 13.7 | 4.20 [1.56, 6.84] |
| Zhang, YF 2021    | 59.9  | 8.36 | 43 | 57.13 | 9.81 | 41 | 9.1  | 2.77 [−1.14, 6.68] |
| Total (95% CI)    | 293   |       |     | 284   |       |     | 100.0% | 3.90 [2.40, 5.40] |

Heterogeneity: Tau\textsuperscript{2} = 2.46; Chi\textsuperscript{2} = 17.58, df = 7 (P = 0.01); I\textsuperscript{2} = 96%

Test for overall effect: Z = 2.48 (P = 0.01)

### Table 3: Study Subgroup Analysis

| Study or Subgroup | Experimental | Control | Mean Difference | Mean Difference |
|-------------------|--------------|---------|-----------------|-----------------|
|                   | Mean | SD | Total | Mean | SD | Total | (%) | IV, Random, 95% CI | IV, Random, 95% CI |
| Chen, MG 2020     | 105  | 131.1 | 43 | 155  | 137 | 39 | 29.9 | −50.00 [−108.17, 8.17] |
| Kang, ZL 2021     | 409.89 | 80.99 | 38 | 463.8 | 93.88 | 38 | 65.1 | −53.91 [−93.33, −14.49] |
| Xiong, XH 2016    | 1,329.4 | 567.3 | 33 | 1,373.2 | 552.1 | 30 | 1.3 | −43.80 [−320.38, 232.78] |
| Zhang, YF 2021    | 435.27 | 320.98 | 43 | 492.62 | 448.13 | 41 | 3.6 | −57.35 [−224.74, 110.04] |
| Total (95% CI)    | 157   |       |     | 148   |       |     | 100.0% | −52.73 [−84.55, −20.91] |

Heterogeneity: Chi\textsuperscript{2} = 0.02, df = 3 (P = 0.01); I\textsuperscript{2} = 0%

Test for overall effect: Z = 3.25 (P = 0.001)

**Figure 2:** (a) The forest plots showed differences in 6MWT, (b) LVEF, and (c) NT-proBNP between CHD patients with and without Baduanjin.
Figure 3: Effects of Baduanjin on indicators including peak VO$_2$ (a), AT VO$_2$ (a), MVV (b), VE, AT (b), O$_2$ pulse (c), and METs (d) of patients with CHD.
and countries, which leads to a poor extrapolation of the results. High-quality RCTs in other regions and with larger sizes are considerable in further research, to evaluate whether Baduanjin has a similar effect on the cardiopulmonary function of CHD patients from other ethnic groups.

5. Conclusion

This meta-analysis indicated that the exercise of Baduanjin is beneficial in improving the recovery of cardiopulmonary function for patients with CHD. There was no significant publication bias in this study, and the results were highly reliable, but the included studies were heterogeneous with low methodological quality. Further high-quality and large-sample RCTs are suggested to be carried out to verify the reliability and extrapolation of the results.

Data Availability

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

Additional Points

(1) Baduanjin can improve the levels of rehabilitation indicators in CHD patients. (2) Baduanjin is beneficial to cardiopulmonary function recovery in patients with CHD. (3) Subgroup analysis suggested a significant recovery effect of Baduanjin on LVEF. (4) This meta-analysis has no significant publication bias, and the results were highly reliable.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

DS-W conceptualized the study and designed the research, did acquisition of data, and drafted the manuscript. JX performed the analysis and interpretation of data and revision of the manuscript. All authors have approved the final paper.

Supplementary Materials

Figure S1: evaluating the methodological quality of included studies. Figure S2: subgroup analyses on LVEF, in termsoffollow-up time, rehabilitation scheme, and new-onset status. Table S1: retrieval strategies and results in PubMed. Table S2: retrieval strategies and results in Embase. Table S3: retrieval strategies and results in the cochrane library. (Supplementary Materials)

References

[1] Y. Tian, P. Deng, B. Li et al., “Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance,” Reviews in Cardiovascular Medicine, vol. 20, no. 1, pp. 27–33, 2019.
[2] K. Deckers, S. H. J. Schievink, M. M. F. Rodriguez et al., “Coronary heart disease and risk for cognitive impairment or dementia: systematic review and meta-analysis,” PLoS One, vol. 12, no. 9, Article ID e0184244, 2017.
[3] L. Anderson, J. P. Brown, A. M. Clark et al., “Patient education in the management of coronary heart disease,” Cochrane Database of Systematic Reviews, vol. 6, no. 6, Article ID Cd008895, 2017.
[4] S. R. McMahon, P. A. Ades, and P. D. Thompson, “The role of cardiac rehabilitation in patients with heart disease,” Trends in Cardiovascular Medicine, vol. 27, no. 6, pp. 420–425, 2017.
Evidence-Based Complementary and Alternative Medicine

[5] A. Akyuz, “Exercise and coronary heart disease,” Advances in Experimental Medicine & Biology, vol. 1228, pp. 169–179, 2020.

[6] L. Anderson, D. R. Thompson, N. Oldridge et al., “Exercise-based cardiac rehabilitation for coronary heart disease,” Cochrane Database of Systematic Reviews, vol. 2016, no. 1, Article ID Cd001800, 2016.

[7] M. F. Bai and X. Wang, “Risk factors associated with coronary heart disease in women: a systematic review,” Herz, vol. 45, no. S1, pp. 52–57, 2020.

[8] S. Nichols, G. McGregor, J. Breckon, and L. Ingle, “Current insights into exercise-based cardiac rehabilitation in patients with coronary heart disease and chronic heart failure,” International Journal of Sports Medicine, vol. 42, no. 1, pp. 19–26, 2021.

[9] Y. Guan, Y. Hao, Y. Guan, and H. Wang, “Effects of Baduanjin exercise on essential hypertension: a meta-analysis of randomized controlled trials,” Medicine (Baltimore), vol. 99, no. 32, Article ID e21577, 2020.

[10] X. Xiong, P. Wang, S. Li, Y. Zhang, and X. Li, “Effect of Baduanjin exercise for hypertension: a systematic review and meta-analysis of randomized controlled trials,” Maturitas, vol. 80, no. 4, pp. 370–378, 2015.

[11] X. Chen, G. Marrone, T. P. Olson et al., “Intensity level and cardiorespiratory responses to Baduanjin exercise in patients with chronic heart failure,” ESC Heart Failure, vol. 7, no. 6, pp. 3782–3791, 2020.

[12] L. Zou, J. E. SasaKi, H. Wang, Z. Xiao, Q. Fang, and M. Zhang, “A systematic review and meta-analysis Baduanjin qigong for health benefits: randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 4548706, 2017.

[13] X. Xiao, J. Wang, Y. Gu, Y. Cai, and L. Ma, “Effect of community based practice of baduanjin on self-efficacy of adults with cardiovascular diseases,” PLoS One, vol. 13, no. 7, Article ID e0200246, 2018.

[14] “Analysis of the effect of baduanjin combined with aerobic endurance training on elderly patients with stable coronary heart disease complicated with chronic heart failure,” Chinese Journal of the Frontiers of Medical Science (Electronic Version), vol. 13, no. 2, pp. 39–42, 2021.

[15] M. G. Chen, X. Liang, L. Kong et al., “Effect Of baduanjin sequential therapy on the quality of life and cardiac function in patients with ami after PCI: a randomized controlled trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 8171549, 2020

[16] “Clinical observation on the effect of baduanjin on life quality of patients with coronary heart disease after stenting,” Bao Jian Wen Hui, vol. 20, pp. 130-131, 2020.

[17] A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” PLoS Medicine, vol. 6, no. 7, Article ID e1000100, 2009.

[18] J. P. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions, Wiley-Blackwell, Hoboken, New Jersey, US, 2008.

[19] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003.

[20] J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002.
[38] W. Kao and M. Jessup, “Exercise testing and exercise training in patients with congestive heart failure,” The Journal of Heart and Lung Transplantation, vol. 13, no. 4, pp. S117–S121, 1994.

[39] M. Yu, S. Li, S. Li, J. Li, H. Xu, and K. Chen, “Baduanjin exercise for patients with ischemic heart failure on phase-II cardiac rehabilitation (BEAR trial): study protocol for a prospective randomized controlled trial,” Trials, vol. 19, no. 1, p. 381, 2018.

[40] B. Ziaeian and G. C. Fonarow, “Epidemiology and aetiology of heart failure,” Nature Reviews Cardiology, vol. 13, no. 6, pp. 368–378, 2016.